These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18847314)

  • 21. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B cell alterations during BAFF inhibition with belimumab in SLE.
    Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
    EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation and characterization of human B lymphocyte stimulator blocking monoclonal antibody.
    Zhuang W; Zhang J; Pei L; Fang S; Liu H; Wang R; Su Y
    Mol Immunol; 2016 Sep; 77():141-7. PubMed ID: 27505709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
    Stohl W
    Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus.
    Prete M; Leone P; Frassanito MA; Desantis V; Marasco C; Cicco S; Dammacco F; Vacca A; Racanelli V
    Lupus; 2018 Oct; 27(12):1926-1935. PubMed ID: 30180771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The discovery and development of belimumab: the anti-BLyS-lupus connection.
    Stohl W; Hilbert DM
    Nat Biotechnol; 2012 Jan; 30(1):69-77. PubMed ID: 22231104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline.
    Ding C; Jones G
    Curr Opin Investig Drugs; 2006 May; 7(5):464-72. PubMed ID: 16729724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
    Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
    J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Belimumab: targeted therapy for lupus.
    Chugh PK; Kalra BS
    Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.
    Stohl W; Scholz JL; Cancro MP
    Curr Opin Rheumatol; 2011 May; 23(3):305-10. PubMed ID: 21330926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series.
    Gualtierotti R; Borghi MO; Gerosa M; Schioppo T; Larghi P; Geginat J; Meroni PL
    Clin Exp Rheumatol; 2018; 36(4):643-647. PubMed ID: 29533753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.
    Mota P; Reddy V; Isenberg D
    Expert Rev Clin Immunol; 2017 Jul; 13(7):667-676. PubMed ID: 27841031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.
    Bishton M; Spencer A; Dickinson M; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):575-8. PubMed ID: 23773449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.